MTCR Research and Charts

MTCR - Metacrine Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2024-02-16 (Delayed quote data )

Last	Change ⇓ 0.00 (%)	Volume 0
	Open	High	Low

8EMA (Daily) 0.00	40EMA (Daily)	50EMA (Daily)	STO (Daily)	MACD Hist (Daily)
8EMA (Weekly) 0.571	40EMA (Weekly) 0.58	50EMA (Weekly) 0.64	STO (Weekly) 80.595	MACD Hist (Weekly) 0.013


Company Profile
Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.